ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP), announced today that it will be presenting at the following investor conferences: JMP Securities Healthcare ConferenceTuesday, September 27, 2011The St. Regis Hotel, New York4:00 p.m. Eastern TimeSpeaker: Jonathan Lewis, M.D., Ph.D., Chief Executive Officer Jefferies 2011 Global Healthcare ConferenceWednesday, September 28, 2011London, UK4:20 p.m. GMTSpeaker: Richard Bagley, President and Chief Operating Officer Dr. Lewis and Mr. Bagley will provide an overview of the Company and its clinical development programs. To access live webcasts of the presentations, please visit the Investor Relations section at www.ziopharm.com. The webcasts will be archived for ninety days. About ZIOPHARM Oncology, Inc.: ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer therapeutics. The Company is currently focused on several clinical programs. Palifosfamide (Zymafos™ or ZIO-201) is a novel DNA cross-linker in class with bendamustine, ifosfamide, and cyclophosphamide and is currently in a randomized, double-blinded, placebo-controlled Phase 3 trial with palifosfamide administered intravenously for the treatment of metastatic soft tissue sarcoma in the front-line setting. The Company is also currently conducting a Phase 1 study of palifosfamide in combination with standard of care for addressing small cell lung cancer, an oral form of palifosfamide continues in preclinical study. Darinaparsin (Zinapar™ or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) currently in a solid tumor Phase I study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. Indibulin (Zybulin™ or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and a quite tolerable toxicity profile. It is currently being studied in Phase 1/2 in metastatic breast cancer. ZIOPHARM is also pursuing the development of novel DNA-based therapeutics in the field of cancer pursuant to a partnering arrangement with Intrexon Corporation. The partnership includes two existing clinical-stage product candidates, both of which are currently in Phase 1.